Armed with positive data from a phase 2b trial, Teva and Sanofi have decided to push their anti-TL1A antibody duvakitug into a phase 3 programme in inflammatory bowel disease (IBD). The results of ...

Teva's business is encountering headwinds, including declining U.S. generics revenue. Read what this biotech plans to do in 2025.

In ulcerative colitis, duvakitug led to clinical remission in ... Also Read: Axsome Therapeutics Resolves Generic Patent Litigation With Teva Over Depression Drug, Analyst Maintains Axsome As ...

Monday, Sanofi and Teva filled in some of the gaps at the 20th Congress of the European Crohn’s and Colitis Organisation. The updated readout shows duvakitug’s effect on key secondary ...

Teva Pharmaceuticals (TEVA), and Sanofi (SNY) presented new, detailed results from the RELIEVE UCCD Phase 2b study of duvakitug, a human IgG1-2 monoclonal antibody targeting TL1A, for the ...

a US affiliate of Teva Pharmaceutical Industries Ltd., today presented new, detailed results from the RELIEVE UCCD phase 2b study of duvakitug, a human IgG1-λ2 monoclonal antibody targeting TL1A ...

Sanofi and Teva Pharmaceuticals, a US affiliate of Teva Pharmaceutical Industries Ltd., today presented new, detailed results from the RELIEVE UCCD phase 2b study of duvakitug, a human IgG1-λ2 ...